Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

被引：0
|
作者：
Yuxin Mu
Xuezhi Hao
Puyuan Xing
Xingsheng Hu
Yan Wang
Teng Li
Jinyao Zhang
Ziyi Xu
Junling Li
机构：
[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Non-small-cell lung cancer; Osimertinib; T790M; Resistance mechanism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2427 / 2433
页数：6
相关论文
共 50 条
  • [21] Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
    Makimoto, Go
    Ohashi, Kadoaki
    Senoo, Satoru
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    INTERNAL MEDICINE, 2019, 58 (11) : 1625 - 1627
  • [22] Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study
    Mehlman, Camille
    Cadranel, Jacques
    Rousseau-Bussac, Gaelle
    Lacave, Roger
    Pujals, Anais
    Girard, Nicolas
    Callens, Celine
    Gounant, Valerie
    Theou-Anton, Nathalie
    Friard, Sylvie
    Tredaniel, Jean
    Blons, Helene
    Dujon, Cecile
    Duchemann, Boris
    Schischmanoff, Pierre Olivier
    Chinet, Thierry
    Leprieur, Etienne Giroux
    LUNG CANCER, 2019, 137 : 149 - 156
  • [23] Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer
    Wang, Nan
    Zhao, Qilin
    Huang, Yutang
    Wen, Chunjie
    Li, Yaji
    Bao, Meihua
    Wu, Lanxiang
    MOLECULAR OMICS, 2023, 19 (03) : 238 - 251
  • [24] Osimertinib Acquired Resistance Mechanisms and Post-Progression Outcomes in Stage IV EGFR Positive Non-Small Lung Cancer
    Patil, T.
    Dimou, A.
    Pacheco, J.
    Smith, D.
    Aisner, D.
    Merrick, D.
    Rusthoven, C.
    Kavanaugh, B.
    Miller, R.
    Schenk, E.
    Camidge, D. R.
    Bunn, P., Jr.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S394 - S394
  • [25] Efficacy and safety of osimertinib plus anlotinib in advanced non-small-cell lung cancer patients after drug resistance
    Wang, Mingzhao
    Zhao, Jun
    Chen, Tong
    Hu, Xingsheng
    Wang, Lin
    Shi, Yuankai
    Liu, Yutao
    THORACIC CANCER, 2023, 14 (10) : 873 - 880
  • [26] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [27] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [28] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Arjan Gower
    Yisong Wang
    Giuseppe Giaccone
    Journal of Molecular Medicine, 2014, 92 : 697 - 707
  • [29] Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
    Gower, Arjan
    Wang, Yisong
    Giaccone, Giuseppe
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (07): : 697 - 707
  • [30] EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance
    Fogli, Stefano
    Polini, Beatrice
    Del Re, Marzia
    Petrini, Iacopo
    Passaro, Antonio
    Crucitta, Stefania
    Rofi, Eleonora
    Danesi, Romano
    PHARMACOGENOMICS, 2018, 19 (08) : 727 - 740
12345